Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95185

UPID:
UNC5C_HUMAN

ALTERNATIVE NAMES:
Protein unc-5 homolog 3; Protein unc-5 homolog C

ALTERNATIVE UPACC:
O95185; Q8IUT0

BACKGROUND:
The Netrin receptor UNC5C, alternatively named Protein unc-5 homolog 3 or C, is crucial for neuronal development, guiding axon repulsion and growth cone dynamics through interaction with NTN1/Netrin-1. It also plays roles in apoptosis as a dependence receptor and in axon guidance independent of DCC, highlighting its multifaceted function in the nervous system.

THERAPEUTIC SIGNIFICANCE:
UNC5C's role in Alzheimer's disease, a condition marked by cognitive decline and amyloid plaque accumulation, underscores its potential as a target for developing treatments aimed at halting or reversing neurodegenerative processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.